SIGA
SIGA Delivers Strong Financial Results in Q4 2025 Amid Heightened Biothreat Risks
SGIA, a leading provider of smallpox antiviral treatment, has reported solid financial results for the fourth quarter of 2025. The company delivered strong revenues and continued to strengthen its position as a key player in global biosecurity efforts. In a recent conference call, SIGA's Chief Executive Officer, Diem